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INTRODUCTION
Stereotactic ablative radiotherapy (SABR) is increasingly 
used to treat limited sites of metastatic relapse (so- called 
oligorecurrence) in the abdomen/pelvis after primary treat-
ment for malignancy.1–3 SABR is ultra hypofractionated 
radiation, delivering large doses per fraction to a highly 
conformal target volume using steep dose gradients in a 
small number of fractions. To safely deliver SABR, effec-
tive immobilisation and accurate target localisation within 
millimetre tolerances using image guidance and online 
correction for interfraction motion and set up errors are 
required.4,5
For linear accelerator- delivered SABR, volumetric image 
guidance is commonly acquired using cone beam computed 
tomography (CBCT).6 In contrast to diagnostic helical CT, 
CBCT image projections are typically acquired over at least 
1–2 min and are susceptible to motion artefacts (including 
from bowel) that manifest after reconstruction into volu-
metric images.7,8
In radiology, hyoscine butylbromide (Buscopan® [Sanofi, 
Reading, UK], herein referred to as buscopan) is routinely 
used to reduce motion artefacts during MRI of the abdomen 
and pelvis (among other examinations).9
https:// doi. org/ 10. 1259/ bjro. 20210045
Objectives: Cone beam computed tomography (CBCT) 
is used for image guidance of stereotactic ablative radi-
otherapy (SABR), but it is susceptible to bowel motion 
artefacts. This trial evaluated the impact of hyoscine 
butylbromide (buscopan) on CBCT image quality and its 
feasibility within a radiotherapy workflow.
Methods: A single- centre feasibility trial 
(ISRCTN24362767) was performed in patients treated 
with SABR for abdominal/pelvic oligorecurrence. 
Buscopan was administered to separate cohorts by intra-
muscular (IM) or intravenous (i.v.) injection on alternate 
fractions, providing within- patient control data. 4- point 
Likert scales were used to assess overall image quality 
(ranging from excellent to impossible to use) and bowel 
motion artefact (ranging from none to severe). Feasi-
bility was determined by patient/radiographer question-
naires and toxicity assessment. Descriptive statistics are 
presented.
Results: 16 patients were treated (8 by IM and 8 by i.v. 
buscopan). The percentage of images of excellent quality 
with/without buscopan was 47 vs 29% for IM buscopan 
and 65 vs 40% for i.v. buscopan. The percentage of 
images with no bowel motion artefact with/without 
buscopan was 24.6 vs 8.9% for IM buscopan and 25.8 
vs 7% for i.v. buscopan. Four patients (25%) reported 
dry mouth. 14 patients (93%) would accept buscopan 
as routine. 11 radiographers (92%) reported no delay in 
treatments.
Conclusions: A trend towards improved image quality/
reduced bowel motion artefact was observed with IM/i.v. 
buscopan. Buscopan was well tolerated with limited 
impact on workflow.
Advances in knowledge: This is the first trial of buscopan 
within a radiotherapy workflow. It demonstrated a trend 
to improved image quality and feasibility of use.
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However, administration of anti- peristaltic agents to reduce 
bowel motion artefacts during radiotherapy has not been previ-
ously investigated. In this prospective trial, we evaluated the 
impact of intramuscular (IM) and intravenous (i.v.) buscopan 




A single- centre, non- randomised feasibility study was under-
taken in Leeds Cancer Centre in patients treated with abdom-
inal/pelvic SABR. The trial was registered on the NIHR Clinical 
Research Network Portfolio (ID40521) and ISRCTN registry 
(ISRCTN24362767). Ethical approval from NHS Health 
Research Authority Research Ethics Committee (referenceXX) 
was granted March 2019. A CONSORT trials checklist is shown 
in Supplementary Material 1
Participants
Participants were identified through Leeds Cancer Centre SABR 
multidisciplinary meeting. Eligible patients were treated with 
SABR for oligorecurrent soft tissue/bone metastatic disease 
in the abdomen/pelvis. Ineligible patients had contraindica-
tions to buscopan: severe/recent cardiac disease, tachyarrhyth-
mias, narrow angle glaucoma, myasthenia gravis, mechanical/
functional bowel obstruction, obstructive uropathy, porphyria, 
allergy to buscopan and concomitant administration of anti-
coagulants (IM buscopan cohort).9,10 All participants provided 
written informed consent.
Interventions
Buscopan was administered to separate cohorts by IM or i.v. 
injection on alternate fractions. Each patient therefore provided 
data without buscopan, acting as a within- person control 
regarding their individual bowel appearance/motion. Initially, 
IM buscopan was used since it was considered that this would 
be more feasible to deliver within a radiotherapy workflow. After 
review of the first three patients treated with IM buscopan and 
concern for limited impact on image quality, a substantial amend-
ment to the protocol was made to administer i.v. buscopan.
IM buscopan (20 mg ml−1) was administered into the buttock 
immediately before the patient entered the treatment room. 
i.v. buscopan (20 mg ml−1) was diluted in 10 ml 0.9% sodium 
Table 1. Summary of end of treatment patient questionnaire data
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**1=’not at all’, 2=’somewhat’, 3=’moderately’, 4=’very much so’
aQuestionnaire data not available for one patient who did not complete radiotherapy as planned due to acute admission
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chloride and administered over 1 min via a peripherally sited 
venous cannula, as per institutional protocol. i.v. buscopan 
was administered once the patient was positioned on the treat-
ment table prior to set- up. The ratio of fractions with/without 
buscopan was 2:1 and 3:2 for 3 and 5 fraction SABR respectively. 
Patient involvement in the study finished after their final SABR 
fraction.
SABR was delivered using a Versa HD™ linear accelerator (Elekta 
AB, Stockholm, Sweden) as 30 Gy in 3–5 fractions on alternate 
days for soft tissue/non- spinal bone lesions and 24 Gy in 3 frac-
tions for spinal lesions. Patients were positioned supine and 
immobilised in a BodyFix® vacuum bag (Elekta). CBCTs were 
acquired using XVI v. 5.04 (Elekta) at baseline (after patient set 
up), pre- treatment (after target matching and application of shifts 
in treatment table position) and post- treatment. The following 
acquisition parameters were used: 120 kV, 20–32 mA, 20–40 ms, 
660–1320 projections. Time from injection to each CBCT was 
recorded. Dietary advice was not provided. For pelvic lesions, 
scanning was undertaken with empty bladder and rectum.
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SABR, stereotactic ablative radiotherapy
**1=’not at all’, 2=’somewhat’, 3=’moderately’, 4=’very much so’
aRadiographer questionnaire data not available for four patients
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Outcomes
The primary end point was improvement in image quality when 
buscopan was given compared with when it was not given and 
was assessed using two 4- point Likert scales; an overall image 
quality scale and a bowel motion artefact scale. The overall image 
quality scale had the following points: 4 (excellent quality), 3 
(satisfactory quality), 2 (poor quality) and 1 (impossible to use). 
The scale was task- orientated; image quality was scored in the 
context of matching to the target. The bowel motion artefact 
scale had the following points: 0 (no artefact), 1 (mild artefact), 2 
(moderate artefact) and 3 (severe artefact). Each scale had been 
internally validated in a retrospective study in which the image 
quality of CBCT was evaluated in patients previously treated 
with abdominal/pelvic SABR.11
Image quality was evaluated concurrently by MB (senior radiog-
rapher) and FS (clinical research fellow) as a consensus score. It 
was considered that this approach was analogous to the use of 
image guidance in clinical practice, where pairs of radiographers 
agree on target matching prior to treatment delivery. Training 
was performed using images from the previously treated 
cohort corresponding to each point on the respective Likert 
scales. Images were viewed in XVI using the following proce-
dure: a random sequence of images per patient was generated 
using Microsoft Excel 2010 (Microsoft Corporation, Redmond, 
Washington, USA) and a third person (not scoring the images) 
loaded each image as per the random sequence. Dates/times 
were concealed from images to ensure scorers were blinded to 
whether buscopan was administered. Exploratory analyses of 
image quality were undertaken for timing of CBCT and whether 
the treated lesion was pelvic (below level of aortic bifurcation) 
versus abdominal and soft tissue vs bone.
Secondary end points were to demonstrate that administra-
tion of IM/i.v. buscopan was feasible within an abdominal/
pelvic SABR workflow and was tolerated by patients. These were 
assessed on the final fraction using a combination of clinician- 
assessed toxicity (using Common Toxicity Criteria for Adverse 
Events (CTCAE) v. 5.0) and patient/radiographer question-
naires.12 The questionnaires used a 4- point Likert scale with the 
following points: 1 (not at all), 2 (somewhat), 3 (moderately) and 
4 (very much so). For patients, questions primarily concerned 
their experience of treatment with buscopan and can be seen 
in Table  1. One radiographer per patient was approached to 
complete a questionnaire. These questions primarily concerned 
the impact of buscopan on workflow and can be seen in Table 2. 
Questionnaire design was based on previously published radio-
therapy/MRI patient questionnaires.13,14
Statistics
This feasibility study was not designed to demonstrate statis-
tical significance; therefore, there was no formal sample size 
calculation.15 Given each patient received 3 scans per 3/5 frac-
tions, a sample of 16 patients provided between 144 and 240 
images and was considered sufficient information. Each patient 
provided data with/without buscopan, acting as a within- person 
control. However, pairing of data to utilise standard statistical 
paired tests was infeasible, with no clear pairing and violation 
Figure 1. Flow diagram showing numbers of participants approached for the study, numbers of patients excluded/recruited and 
numbers of patients who completed the study.
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of the assumption of independent samples due to pairing across 
multiple scan/time points for the same patient. More sophisti-
cated approaches, that account for the complex data structure, 
such as mixed modelling, were considered unsuitable for the 
number of patients. Therefore, descriptive statistics are presented 
including median and interquartile range (IQR). To account for 
differences in numbers of images with/without buscopan and 
intrapatient correlation in bowel motion, image quality scores 




The trial schema is shown in Figure 1. 10 patients were excluded. 
16 patients commenced treatment (8 in the IM cohort and 8 in 
the i.v. cohort); of these, one patient in the i.v. cohort experienced 
vertebral collapse and SABR was stopped early. The first patient 
was recruited September 2019 and the final patient completed 
treatment January 2021. Study recruitment was paused for 6 
months from March to July 2020 during the Covid-19 pandemic.
Baseline demographic and clinical characteristics of the patients 
are shown in Supplementary Material 1. 11 patients received 
5- fraction SABR and 5 received 3 fractions. Eight lesions were 
in soft tissue and eight were in bone. 10 lesions were pelvic and 
6 were abdominal.
Primary endpoint
Figure 2 illustrates the impact of IM and i.v. buscopan on bowel 
motion artefact in CBCT images.
16 patients were included in the image quality analyses (8 in IM 
cohort and 8 in i.v. cohort); 127 images with buscopan (65 and 62 
in IM and i.v. cohorts respectively) and 88 without buscopan (45 
and 43 in IM and i.v. cohorts respectively). One image (without 
buscopan) in the i.v. cohort was excluded because of scan failure.
For patients who received IM buscopan, the percentage of images 
of excellent quality with/without buscopan was 47 vs 29%. For 
patients who received i.v. buscopan, the percentage of images 
of excellent quality with/without buscopan was 65 vs 40%. A 
summary of overall image quality and the proportion of images 
corresponding to each point on the scale is shown in Table 3. The 
proportion of scores per patient is illustrated in Figure 3. Indi-
vidual patient data is shown in Supplementary Material 1.
For patients who received IM buscopan, the percentage of images 
with no bowel motion artefact with/without buscopan was 24.6 
vs 8.9%. For patients who received i.v. buscopan, the percentage 
of images of excellent quality with/without buscopan was 25.8 
vs 7%. A summary of bowel motion artefact and the proportion 
of images corresponding to each point on the scale is shown in 
Table  4. The proportion of scores per patient is illustrated in 
Figure  3. Individual patient data are shown in Supplementary 
Material 1.
Summaries of image quality by timing of CBCT and for pelvic 
vs abdominal and soft tissue versus bone lesions are shown in 
Supplementary Material 1.
Median time (IQR) from injection to baseline, pre- treatment 
and post- treatment imaging was 10 min (7–11) and 7 min (5–8), 
14 min (13–17) and 12 min (11–15) and 21 min (17–26) and 
20 min (17–26) for IM and i.v. buscopan respectively.
Secondary end points
A summary of patient questionnaire data for 15 patients is shown 
in Table 1. Questionnaire data were not available for the patient 
who did not complete SABR as planned. 14 patients (93%) 
who completed questionnaires would accept buscopan prior to 
routine SABR treatment.
A summary of radiographer questionnaire data for 12 radiog-
raphers is shown in Table 2. Questionnaires were offered to 16 
radiographers and 12 accepted. 11 radiographers (92%) reported 
no delay in patients’ treatments as a result of buscopan.
Toxicity
A summary of acute toxicities is shown in Table 5. No ≥Grade 3 
toxicities were observed.
DISCUSSION
This is the first study to evaluate the impact of anti peristaltic 
agents in radiotherapy/on CBCT image quality. We observed 
a trend to improved overall image quality when buscopan 
was given. The percentage difference in image quality without 
buscopan between the IM and i.v. cohorts demonstrates consid-
erable inter patient variation, possibly as a result of individual 
bowel appearance/motion and this validates the approach of 
Figure 2. Planning CT and CBCT images with/without IM and 
i.v. buscopan for three patients. GTV and PTV are shown in 
each image. CBCT, cone beam CT; GTV, gross tumour volume; 
PTV, planning target volume.
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using patients as their own control. There was also a trend to 
reduced bowel motion artefacts with buscopan. Since the study 
was not powered to detect a statistically significant improvement 
in image quality, these findings should be considered as a signal 
of the anti peristaltic effect of buscopan.
The administration of buscopan appeared to be feasible. In 
general, IM and i.v. buscopan was well tolerated by patients as 
evidenced by toxicity assessment/questionnaire responses. Dry 
mouth and injection site discomfort were related to buscopan, 
with abdominal discomfort/diarrhoea more likely due to SABR. 
Previous prospective/randomised studies of buscopan during 
abdominal/pelvic MRI differ in the toxicities reported. Some 
reported blurred vision in up to 20% of participants, with dry 
mouth (63%), warmth (20%), dizziness (11%) and palpitations 
(6%) also described in a study by Johnson et al.18–21 Rate of 
administration of i.v. buscopan was not described in Johnson 
et al, but it is possible that administration over 1 min mini-
mised toxicity in our i.v. cohort.22 Other studies reported no 
toxicity, although Johnson et al used patient questionnaires to 
assess toxicity.20,23–26 Radiographer questionnaire responses 
suggested that buscopan did not negatively impact on workflow. 
This is despite no specific slot for cannulation/administration of 
buscopan having been booked for patients, which would likely 
aid patient flow in routine practice.
Several previous prospective and two randomised radiology 
studies have evaluated the impact of buscopan on image quality 
for MRI of the abdomen and pelvis.21,23–29 Heterogeneity exists 
between these studies for the route of buscopan administration, 
the method of image analysis (qualitative Likert- type scales 
versus measurement of image noise) and whether bowel is 
evaluated or another organ/lesion. Nevertheless, in prospective 
studies administration of IM/i.v. buscopan was associated with 
significantly improved image quality, reduced bowel motion 
artefacts and improved organ/lesion identification.21,25–29 In two 
randomised studies (which quantified image noise with/without 
buscopan), a significant reduction in bowel artefact noise was 
observed when buscopan was administered.23,24
The magnitude of improvement in image quality in our study 
was modest. However, accepting differences in measurement 
between studies the improvements we observed are comparable 
to the differences in overall image quality/bowel motion artefact 
of approximately 0.5–1.0 on 5- point scales reported in prospec-
tive studies of buscopan in MRI abdomen/pelvis.21,26,27 In 
contrast to radiology where the clarity of lesion visualisation may 
be of critical diagnostic importance, the clinical benefits of the 
improvements in image quality/reduced bowel motion artefacts 
on CBCT that we observed are less easy to define. The percentage 
of images scored as poor for overall quality with buscopan was 
almost half that without. However, all of the patients in the study 
proceeded with treatment regardless of the quality of their images 
and no image was scored as impossible to use, which suggests 
that for CBCT- guided SABR poor quality may be good enough. 
The published MRI data, combined with the feasibility that we 
demonstrated of delivering buscopan within a SABR workflow, 
suggest that a useful application of buscopan could be for MR 
linac- delivered SABR. A concern with the delivery of ablative 
doses in the abdomen and pelvis is the risk of toxicity, especially 
concerning bowel. The greater soft tissue visualisation afforded 
by MRI compared with CBCT and online reoptimisation may 
provide the opportunity to adapt the delivered dose based on the 
daily position of adjacent OARs such as bowel.30,31 This approach 
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8 45 3.0 (3.0–3.3) 13 (28.9%) 29 (64.4%) 3 (6.7%) 0
Images with 
i.v. buscopan












16 88 3.0 (3.0–4.0) 30 (34.1%) 46 (52.3%) 12 (13.6%) 0
IM, intra muscular; IQR, inter quartile range; IV, intravenous; min, minimum; max, maximum
*4=excellent quality, 3 = satisfactory, 2 = poor, 1 = impossible to use
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would require confidence in clearly delineating both the target 
and OARs. Buscopan could therefore be an important adjunct to 
improve the quality of images for bowel delineation, for which 
deformable image registration/autocontouring strategies remain 
under investigation.32 Ease of target/bowel visualisation, time 
taken for delineation and the extent/dosimetric consequences 
of intrafraction bowel motion with/without buscopan could be 
endpoints measured within a future trial.
Although our study was not designed to compare IM and i.v. 
buscopan, we observed similar image quality scores by both 
administration routes, with slightly improved summary data for 
i.v. buscopan. We did not observe any trends in image quality 
based on the timing of CBCT. Limited data exist concerning the 
onset and duration of anti- peristaltic effects by different routes 
of administration, but they approximately support action of 
buscopan within our time window between first and last CBCT. 
Previous studies of buscopan in small bowel cine MRI reported 
approximate onset of action of i.v. buscopan and IM buscopan of 
<90 sec and 5 min respectively.19,33 Mean duration of action was 
reported to be 21–23 min and approximately 18 min for i.v. and 
IM buscopan respectively. Large variations between participants 
in the onset, extent and duration of response were observed in 
these small studies, especially concerning IM buscopan. It was 
speculated that this could be due to slower/less reliable absorp-
tion of drug via the IM route.33 However, other studies that 
evaluated the impact of buscopan on image quality of abdom-
inal MRI administered IM buscopan around 20 min prior to the 
examination with persisting anti- peristaltic effects.34,35 All of 
this means that, while the MRI data support greater rapidity/reli-
ability of anti- peristaltic effect with i.v. buscopan, it might still be 
possible to observe a benefit in reduction in CBCT bowel motion 
artefact with IM buscopan if cannulation/administration of i.v. 
buscopan is not practical.
A further consideration concerns the location of the treated 
lesion. In this study, 39% of images without buscopan were scored 
as containing severe bowel motion artefacts, although only 14% 
Figure 3. In Figure 3A–B, overall image quality scores are shown with/without buscopan for each patient treated with IM buscopan 
(A, patients 1–8) and i.v. buscopan (B, patients 9–16). 4 = excellent image quality, 3 = satisfactory image quality and 2 = poor image 
quality. IM, intramuscular.
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of images were considered to be of overall poor quality. This 
discrepancy may be related to the scoring process we used, where 
overall image quality was assessed in the context of the ability 
to match to the target. 50% of lesions occurred in bone, where 
the automatic registration between planning CT and CBCT typi-
cally works well.36 These patients were included where bowel was 
close to the lesion but it meant that an image could be scored 
as being of overall satisfactory quality despite the presence of 
severe bowel motion artefact, and therefore buscopan may have 
less impact on matching for bone lesions. We also observed infe-
rior image quality with/without buscopan for abdominal lesions 
compared with pelvic lesions (median bowel motion artefact 
score 3 vs 1), which is likely secondary to the influence of respi-
ratory motion. Few upper abdominal soft tissue lesions were 
treated during the study period but, for these, the application of 
motion management strategies such as breath- hold/respiratory 
gating in combination with buscopan could be investigated.37,38
This study has several limitations. The number of patients was 
small and there was no statistical comparison of image quality 
with/without buscopan. Our methods of image assessment were 
inherently subjective and our use of a consensus score meant that 
the results could have been over influenced by one of the scorers. 
However, we used example images for training and similar Likert 
scales were used in many of the prospective radiology studies of 
buscopan in MRI abdomen/pelvis. An alternative approach of 
quantitative assessment of image noise may be influenced by 
patient motion/variations in acquisition of regions of interest 
for measurement.20,21,23,25–27,29 Other factors, such as soft tissue 
contrast, may influence CBCT image quality but we did not 
attempt to incorporated this into our qualitative image assess-
ment.39 Other methods of improving CBCT image quality by 
reduction of image noise and motion artefacts exist, such as dual- 
energy CT, anti scatter grids, beam filters and reconstruction 
algorithms.40,41 However, CBCT systems with advanced capabil-
ities may not yet be widely implemented in radiotherapy depart-
ments, meaning that there remains a value in investigating the 
impact of anti peristaltic agents on bowel motion artefacts. Some 
data were missing, which may have influenced our conclusions 
regarding the feasibility of IM/i.v. buscopan; toxicity assessment/
patient questionnaires from one patient who did not complete 
SABR and radiographer questionnaires from four patients.
Figure 4. In Figure  4A–B, bowel motion artefact scores are shown with/without buscopan for each patient treated with IM 
buscopan (A, patients 1–8) and i.v. buscopan (B, patients 9–16). 0 = no artefact, 1 = mild artefact, 2 = moderate artefact and 3 = 
severe artefact.
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CONCLUSION
A trend to improved image quality was observed with buscopan 
and its use in a SABR workflow appears to be feasible. The clin-
ical benefits of buscopan should be investigated and might be 
best evaluated as part of an MR- guided adaptive SABR workflow.
In Figure 2A–C and a planning CT for a right external iliac nodal 
metastasis is shown in A, CBCT with IM buscopan in B and 
CBCT without IM buscopan in C. Reduced streak artefact from 
bowel gas is apparent in B compared with C.
In Figure 2D–F and a planning CT for a left external iliac nodal 
metastasis is shown in D, CBCT with i.v. buscopan in E and 
CBCT without i.v. buscopan in F. Reduced streak artefact from 
bowel gas is apparent in E compared with F.
In Figure 2G–I and a planning CT for a pancreatic tail metastasis 
is shown in G, CBCT with i.v. buscopan is shown in H and CBCT 
without i.v. buscopan is shown in I. Despite some apparent reduc-
tion in bowel motion artefact in H compared with I, persistent 
artefact is shown in H and is likely related to respiratory motion.




































8 45 2.0 (1.0–2.6) 4 (8.9%) 15 (33.3%) 11 (24.4%) 15 (33.3%)
Images with 
i.v. buscopan












16 88 2.0 (1.0–3.0) 7 (8%) 31 (35.2%) 16 (18.2%) 34 (38.6%)
IM, intramuscular; IQR, inter quartile range; IV, intravenous
*0=no bowel motion artefact, 1 = mild bowel motion artefact, 2 = moderate bowel motion artefact, 3 = severe bowel motion artefact
Table 5. Summary of acute toxicity data
Acute toxicity CTCAE gradea
Total number of 
patients (% of 16)b
Number of patients 
treated with IM 
buscopan (% of 8)
Number of patients treated 
with i.v. buscopan (% of 8)
None 6 (37.5%) 4 (50.0%) 2 (25.0%)
Dry mouth 1 3 (18.8%) 1 (12.5%) 2 (25.0%)
  2 1 (6.3%) 1 (12.5%)
Injection site discomfort/
bruising
1 2 (12.5%) 1 (12.5%) 1 (12.5%)
Cannula removal 
discomfort
1 1 (6.3%) 1 (12.5%)
Abdominal pain 1 1 (6.3%) 1 (12.5%)
Diarrhoea 1 4 (25.0%) 2 (25.0%) 2 (25.0%)
CTCAE, Common Toxicity Criteria for Adverse Events; IM, intramuscular; IV, intravenous
aToxicity graded as per Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0
bTotal exceeds 100% since some patients reported more than one toxicity
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